0.00Open0.00Pre Close0 Volume0 Open Interest15.00Strike Price0.00Turnover172.69%IV-38.76%PremiumAug 16, 2024Expiry Date4.19Intrinsic Value100Multiplier24DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.6955Delta0.0735Gamma2.21Leverage Ratio-0.0335Theta-0.0068Rho-1.53Eff Leverage0.0097Vega
Profound Medical Stock Discussion
Profound Medical Announces Category 1 CPT Codes Proposed CY2025 Rule for TULSA to Treat Prostate Diseases
Profound Medical announced the U.S. Centers for Medicare and Medicaid Services (CMS) proposed a Category 1 CPT code for Transurethral Ultrasound Ablation (TULSA), effective January 1, 2025. This includes three physician codes for different procedural scenarios, introducing greater billing flexibility for pre and post-procedure visits.
TULSA will be recognize...
NEWS
Growing Body of Clinical Evidence Points to the Potential of Profound Medical’s TULSA Procedure Becoming a Mainstream Treatment Modality Across the Entire Prostate Disease Spectrum
Profound Medical Corp.'s TULSA procedure is gaining recognition as a mainstream treatment for prostate diseases, with 25 scientific research presentations this year alone. The clinical evidence showcases TULSA's efficacy in treating a diverse range of patients with localized prostate c...
No comment yet